You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 石藥集團(1093.HK)漲超4% 2020年淨利同比增加38.9%
格隆匯 03-16 10:56
格隆匯3月16日丨石藥集團(1093.HK)漲超4%,報9.85港元,高見9.88港元創近半年新高,總市值1179億港元。石藥集團昨日公吿,於截至2020年12月31日止年度,集團收入增加12.8%至人民幣249.42億元,股東應占溢利增加38.9%至人民幣51.60億元,每股基盈利相應增加至人民幣43.16分。董事會建議派發2020年末期股息每股9港仙。成藥方面,神經系統疾病產品錄得銷售收入74.14億元,增加1.5%。其中恩必普的銷售收入增加17.4%,歐來寧減少63.6%。抗腫瘤產品錄得銷售收入62.94億元,增加29.0%。抗感染產品錄得銷售收入27.08億元,減少7.9%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account